Key result
Gliflozins reduce CV death, HF hospitalizations, and major adverse events vs placebo in heart failure.
Why the study?
Recent studies showed that gliflozins reduce cardiovascular death and HF hospitalization, but further studies were needed to confirm these findings and establish their place in HF therapy.
Do gliflozins reduce the risk of cardiovascular death, hospitalization for heart failure, and adverse cardiovascular events in patients with heart failure?
Systematic Review (n=25,960)
Do gliflozins reduce the risk of cardiovascular death, hospitalization for heart failure, and adverse cardiovascular events in patients with heart failure?
This systematic review confirms that SGLT-2 inhibitors significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with heart failure.
Answers are grounded in this paper and cite their sources.
Supports routine gliflozin use in heart failure; confirms CV benefits in large-scale evidence synthesis.
Background: Heart Failure (HF) is a public health problem with high morbidity and mortality rates, as well as resource consumption. Sodium-glucose cotransporter type 2 inhibitors (SGLT-2 inhibitors), originally developed for type 2 diabetes, have become an attractive therapeutic option for HF. Recent studies have shown that gliflozins, a type of SGLT-2 inhibitor, reduce the risk of cardiovascular death and hospitalization for HF compared to placebo. Further studies are needed to confirm these findings and establish their place in the current therapy for HF. Material and methods: A systematic review of studies published in PUBMED evaluating the use of gliflozins, a subtype of InSGLT-2, in patients with heart failure was performed. Results: Based on the articles analyzed, a total of 25,960 patients with heart failure were included, who were studied in 4 different studies. Conclusion: The use of gliflozins in patients with heart failure was found to be associated with a significant reduction in the risk of cardiovascular death, hospitalization for heart failure, and adverse cardiovascular events compared with placebo
No takes yet. Share an insight, caveat, or question.
Brustolin et al. (2023) conducted a systematic review in Heart Failure (n=25,960). Gliflozins (SGLT-2 inhibitors) vs. Placebo was evaluated on Cardiovascular death, hospitalization for heart failure, and adverse cardiovascular events. Gliflozins significantly reduced the risk of cardiovascular death, hospitalization for heart failure, and adverse cardiovascular events compared with placebo in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: